Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
about
The use of nonhuman primate models in HIV vaccine developmentThe hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a reviewThe failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?HIV-Host Interactions: Implications for Vaccine DesignCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionTherapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuckNonhuman primate models for HIV/AIDS vaccine developmentAAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing ActivityViral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaquesPrevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gelEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Vaccine design for CD8 T lymphocyte responsesNovel viral vectored vaccines for the prevention of influenza.Human immunodeficiency virus vaccine trialsImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersEffective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers.Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV.HIV-1 vaccine development after STEP.Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challengeAcute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge.Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaquesIs an HIV vaccine possible?Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challengeCytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaquesImpact of MHC class I diversity on immune control of immunodeficiency virus replication.Novel adenovirus vector-based vaccines for HIV-1.New approaches to design HIV-1 T-cell vaccines
P2860
Q21563403-2E38E104-69AE-49DD-8B46-D590D48A524CQ24630490-2599C386-C1F5-476E-AFA7-494CEA2C1139Q24652185-D832C03F-2E7F-48D4-AC70-22EDB4AA5FACQ26765966-EA995195-ADC9-46DC-98D9-157FDBF4C824Q26775082-47778FEF-0A70-4ADD-BD6E-AA1AEA92C1E0Q26828598-8BBF728A-7E75-4608-A493-0DA0807584BFQ26861148-06380540-AFE8-4499-81DF-303AE8826324Q27318266-545AAACB-0CAD-48FD-92B1-F2C072B315DEQ27349889-9757AFAF-BF1C-4056-9024-C04D56C68B61Q28473376-6EE04A8B-3B45-45C5-A135-5709F94191FCQ28972526-A789BBC3-B42F-4551-B088-34FF3888B850Q30378897-3E94A8A0-B846-42EE-B260-9C493A98A040Q30379200-FB1CE56F-5EBC-4F76-AA7C-88137A485781Q30411492-EC5DFCA3-323A-450F-B27C-FDC62CCAE8EAQ30418570-57FDB342-3849-4792-AB1F-156515A6B416Q30424366-56C9F25A-697F-4934-8636-06FFAC78A512Q33402455-F3E1A01D-A522-4F35-AB80-38F6514A41ACQ33444658-98BD6066-24F4-4232-8E02-5AE30EACE0A1Q33558348-406408F1-67FD-48B3-8AAB-D66F86C1120EQ33565035-C9C37BC1-CD28-4886-AAFE-E376DCF7BFABQ33578049-606316E8-FC0D-483E-A3C5-93A286142F6DQ33603602-A74EFAEE-D417-4BAA-8717-D5F4B4974D8CQ33611719-929B70BA-EDB6-4AC5-A848-26187E7318DDQ33638458-7E826ADF-897F-4E49-900F-861CFACA881AQ33642318-3EA17144-99CD-4A46-93F8-6F3720716125Q33657468-6A70835D-FBAA-44EA-B17B-4003D0EEB5B6Q33676444-599037D2-A478-44E3-BD82-DC6C0D71FD15Q33715758-CA856ACF-3272-442C-AA63-7AD61B4148E7Q33744109-B6369C97-7D50-4A0A-9CD5-35CBEEC4254EQ33749827-9B56C17A-EF8F-4E40-AA0F-057866D55DEEQ33807535-A0AA21B3-7E9C-4CC5-AF41-0AFF25EE25FEQ33826671-3E54C9F9-4AA6-489A-B4C9-E4E401BEBF65Q33839468-B3E573B4-5E0F-4F02-BA1A-545EF50D3DCEQ33877458-BB205AB9-AA6E-43AA-84B5-C232E43AB8F0Q33946263-49BBFBB4-3706-4CD0-B62B-9C3C3398ED16Q34178259-5B91411A-D7C1-4E47-B13B-90FEDEC4122BQ34228494-14DFA7B7-86F6-4DE2-81D7-E9E31DD32547Q34235198-541A98AA-244F-4B41-821D-D88E996054DEQ34257640-4E9DAF16-934D-470F-AAE7-A5FEE5973059Q34274849-F75E0894-8D05-4FD3-8438-EEE50ACBAFF2
P2860
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@ast
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@en
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@nl
type
label
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@ast
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@en
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@nl
prefLabel
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@ast
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@en
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@nl
P2093
P2860
P50
P921
P1433
P1476
Attenuation of simian immunode ...... vaccine vectors expressing Gag
@en
P2093
Adrian B McDermott
Aimin Tang
Andrew J Bett
Ansu Bagchi
Anthony Carella
Arthur Fridman
Daniel C Freed
Danilo R Casimiro
Emilio A Emini
Fubao Wang
P2860
P304
15547-15555
P356
10.1128/JVI.79.24.15547-15555.2005
P407
P577
2005-12-01T00:00:00Z